In the last trading session, 1.1 million Exagen Inc (NASDAQ:XGN) shares changed hands as the company’s beta touched 1.39. With the company’s per share price at $5.02 changed hands at $1.14 or 29.38% during last session, the market valuation stood at $88.54M. XGN’s last price was a discount, traded about -23.9% off its 52-week high of $6.22. The share price had its 52-week low at $1.30, which suggests the last value was 74.1% up since then. When we look at Exagen Inc’s average trading volume, we note the 10-day average is 0.1 million shares, with the 3-month average coming to 151.43K.
Analysts gave the Exagen Inc (XGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.33. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended XGN as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Exagen Inc’s EPS for the current quarter is expected to be -0.24.
Exagen Inc (NASDAQ:XGN) trade information
Instantly XGN was in green as seen at the end of in last trading. With action 23.65%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 22.44%, with the 5-day performance at 23.65% in the green. However, in the 30-day time frame, Exagen Inc (NASDAQ:XGN) is 62.46% up. Looking at the short shares, we see there were 52214.0 shares sold at short interest cover period of 3.12 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need a downside of -0.4% from its current market value. According to analyst projections, XGN’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a 0.4% surge from its current level, while the stock would need to tank 0.4% for it to hit the projected low.
Exagen Inc (XGN) estimates and forecasts
Data shows that the Exagen Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 146.08% over the past 6 months, a 34.33% in annual growth rate that is considerably higher than the industry average of 12.70%. Year-over-year growth is forecast to reach 6.05% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 13.85M. 5 analysts are of the opinion that Exagen Inc’s revenue for the current quarter will be 14.92M. The company’s revenue for the corresponding quarters a year ago was 13.77M and 14.41M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.62%. The estimates for the next quarter sales put growth at 3.50%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 2.69%. The 2025 estimates are for Exagen Inc earnings to increase by 33.46%.
XGN Dividends
Exagen Inc is expected to release its next quarterly earnings report in March.
Exagen Inc (NASDAQ:XGN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 29.74% of Exagen Inc shares while 57.22% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 81.43%. There are 57.22% institutions holding the Exagen Inc stock share, with RTW INVESTMENTS, LP the top institutional holder. As of 2024-06-30, the company held 8.4253% of the shares, roughly 1.51 million XGN shares worth $2.75 million.
COWEN AND COMPANY, LLC holds the second largest percentage of outstanding shares, with 4.9674% or 0.89 million shares worth $1.62 million as of 2024-06-30.
